Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 313,747 | 127,328 | -123,756 | -57,479 | -278,157 |
| Depreciation Amortization | 55,658 | 42,152 | 28,349 | 14,405 | 56,670 |
| Income taxes - deferred | -2,198 | 24,972 | 19,374 | 9,639 | -106,762 |
| Accounts receivable | -359,963 | -544,210 | -144,347 | -7,434 | -86,550 |
| Accounts payable and accrued liabilities | 75,066 | 249,920 | 26,411 | -155,737 | 91,093 |
| Other Working Capital | -444,782 | -371,629 | -166,969 | -217,046 | -214,084 |
| Other Operating Activity | 886,552 | 831,992 | 396,354 | 295,338 | 529,478 |
| Operating Cash Flow | $524,080 | $360,525 | $35,416 | $-118,314 | $-8,312 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 497,176 | 511,050 | -4,349 | 122,739 | -63,246 |
| PPE Investments | -58,697 | -35,405 | -23,263 | -8,970 | -34,277 |
| Purchase Of Investment | 0 | 0 | 0 | 0 | -19,200 |
| Other Investing Activity | -2,150 | -2,150 | 0 | 0 | -117 |
| Investing Cash Flow | $436,329 | $473,495 | $-27,612 | $113,769 | $-116,840 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 613,967 | 608,647 | N/A | N/A | N/A |
| Debt Repayment | -1,169,185 | -1,102,659 | N/A | N/A | N/A |
| Common Stock Issued | 250,028 | 208,327 | 130,587 | 49,365 | 302,951 |
| Other Financing Activity | 0 | -64,822 | -32,746 | -5,281 | -8,792 |
| Financing Cash Flow | $-305,190 | $-350,507 | $97,841 | $44,084 | $294,159 |
| Exchange Rate Effect | 34,936 | 40,637 | 41,564 | 14,058 | -15,239 |
| Beginning Cash Position | 968,652 | 968,652 | 968,652 | 968,652 | 814,884 |
| End Cash Position | 1,658,807 | 1,492,802 | 1,115,861 | 1,022,249 | 968,652 |
| Net Cash Flow | $690,155 | $524,150 | $147,209 | $53,597 | $153,768 |
| Free Cash Flow | |||||
| Operating Cash Flow | 524,080 | 360,525 | 35,416 | -118,314 | -8,312 |
| Capital Expenditure | -58,697 | -35,405 | -23,263 | -8,970 | -34,277 |
| Free Cash Flow | 465,383 | 325,120 | 12,153 | -127,284 | -42,589 |